default author photo

Howard Burris

Tennessee Oncology - Sarah Cannon Research Institute

United Kingdom

  • Tennessee Oncology - Sarah Cannon Research Institute

SCHOLARLY PAPERS

1

DOWNLOADS

82

TOTAL CITATIONS

0

Scholarly Papers (1)

Actions:
Email selected abstracts
1.

Pooled Analysis of Safety and Dose Reductions in the MONALEESA-2, -3, and -7 Phase III Trials on Ribociclib Plus Endocrine Therapy to Treat Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

Number of pages: 22 Posted: 29 Oct 2020
Howard Burris, Arlene Chan, Aditya Bardia, J. Thaddeus Beck, Joohyuk Sohn, Patrick Neven, Debu Tripathy, Seock-Ah Im, Stephen Chia, Francisco J. Esteva, Lowell Hart, Juan Pablo Zarate, Antonia Ridolfi, Karen Rodriguez-Lorenc and Denise A. Yardley
Tennessee Oncology - Sarah Cannon Research Institute, Curtin University, Harvard Medical School - Massachusetts General Hospital Cancer Center, Highlands Oncology Group, Yonsei University Health System - Severance Hospital, KU Leuven - Department of Gynecologic Oncology, University of Texas at Houston - Department of Breast Medical Oncology, Seoul National University - Department of Internal Medicine, BC Cancer Agency (BCCA), NYU Langone Health, Sarah Cannon Research Institute - Florida Cancer Specialists, Novartis Pharmaceuticals Corporation, Novartis Pharmaceuticals Corporation, Novartis Pharmaceuticals Corporation and Tennessee Oncology - Sarah Cannon Research Institute
Downloads 82 (790,029)

Abstract:

Loading...

ribociclib, breast cancer, CDK4/6 inhibitor, endocrine therapy